Haryana minister Anil Vij tests COVID-19 positive days after participating in vaccine trial

-

Haryana health minister Anil Vij, who took part in coronavirus vaccine trials a little over two weeks ago, said on Saturday that he has tested positive for the virus.

The minister also urged all those who had come in close contact with him to get themselves tested.

"I have been tested corona positive. I am admitted in Civil Hospital Ambala Cantt. All those who have come in close contact to me are advised to get themselves tested for corona," he tweeted.

Vij had participated in the third phase trial of Bharat Biotech's Covaxin on 20 November. He had earlier announced on Twitter that he will be the first volunteer in his state for the anti-COVID vaccine.

"The antibodies against the infection build up in a human being only after a specific number of days pass after the second dose of the vaccine is taken, since this is a two-dose vaccine. The minister in question has taken only one dose of the vaccine," the Union Health Ministry said after Vij's announcement.

Meanwhile, Bharat Biotech has reacted to the development as well.

"Covaxin clinical trials are based on a two-dose schedule, given 28 days apart. The vaccine efficacy will be determined 14 days post the second dose. Covaxin has been designed to be efficacious when subjects receive both doses," ANI quoted Bharat Biotech as saying.

"The phase-3 trials are double-blinded and randomized, where 50 percent of subjects (participants in the trial) receive vaccine and 50 percent of subjects receive placebo," said Bharat Biotech.

Vij's media coordinator Vijender Chauhan said the minister was in Chandigarh on Friday afternoon and had reported fatigue later.

Hindustan Times quoted Chauhan as saying: "He got tested himself today morning and the result is positive. The staff will be tested today itself."



from Firstpost India Latest News https://ift.tt/39KQFre
FP Staff

Comments

Post a Comment

Popular posts from this blog

Both COVID-19 vaccine doses needed for good protection against B16172 variant

-
It’s been a concerning few weeks in the UK, with the B16172 variant first taking hold and then spreading to become dominant. This more infectious form of the virus, initially identified in India, is what we’re now going to have to live with – unless it is out-competed by another variant in the future. Worryingly, experts had predicted that B16172 might be able to escape some of the effects of vaccines, which if true would threaten to derail the UK’s plans to finish lifting restrictions from the end of June. However, Public Health England (PHE) has looked at the ability of various variants to evade immunity and says that the UK’s vaccines remain effective against the variants circulating, including B16172. On the surface, this looks like good news. But delve a bit deeper, and things get more complicated, says Paul Hunter, professor of medicine at the University of East Anglia. PHE’s research found a little drop-off in protection against B16172 among people who were fully vaccinated.
Read more

New coronavirus variant emerge in India: How should our COVID response change?

-
Image
After genome sequencing of over 10,000 COVID-19 cases in India, researchers have discovered a new variant with two new mutations which may be better at evading the immune system. In 15-20 percent of samples from the Indian state of Maharashtra (the state accounting for 62 percent of cases in the country) a new, double mutation in key areas of the virus has been detected. These are now known as the E484Q and L452R mutations. What makes the variant different? Both these mutations are concerning because they are located in a key portion of the virus – the spike protein – that it uses to penetrate human cells. Spike proteins attach via a “receptor binding domain”, meaning the virus can attach to receptors in our cells. These new mutations include changes to the spike protein that make it a “better fit” for human cells. This means the virus can gain entry more easily and multiply faster. Given what we have seen with other similar mutations , it might also make it harder for our immu
Read more

Aditya L1 Mission: Spacecraft is nearing its final phase, says ISRO chief

-
Aditya L1 spacecraft is nearing its final phase, and manoeuvres to enter the L1 point are expected to be completed by January 7, 2024, according to ISRO Chairman S Somanath. “Aditya is on the way. I think it has reached almost its final phase,” the ISRO chief told PTI on the sidelines of an event organised at VSSC to commemorate the 60th year of the First Sounding Rocket Launch. Aditya L1, India’s first space-based mission to study the Sun, was successfully launched on September 2 from the Satish Dhawan Space Centre (SDSC) in Sriharikota. The spacecraft, after travelling about 1.5 million km from Earth over 125 days, is expected to be placed in a Halo orbit around the Lagrangian point L1, considered closest to the Sun. He said that the last preparations for the spacecraft’s entry into the L1 point are currently underway incrementally.”Possibly by January 7th, the final manoeuvres will be done for entering into the L1 point,” Somanath added. Among other tasks, it will capture and tr
Read more